title: Modeling of presymptomatic and symptomatic stages of parkinsonism in mice.
abstract: A degradation of the nigrostriatal dopaminergic (DA-ergic) system is the key component of pathogenesis of Parkinson's disease (PD). Initial clinical symptoms appear 20-30 years after the onset of neurodegeneration, at a 70% DA depletion in the striatum and a 50% loss of nigral DA-ergic neurons. Low efficacy of the therapy might be improved if preclinical diagnostics and preventive therapy are developed. The development of appropriate experimental models should precede clinical trials. This multidisciplinary study first managed to model in mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) all together the following stages of parkinsonism: (a) the early presymptomatic stage manifested by a subthreshold degeneration of axons and DA depletion in the striatum without loss of nigral cell bodies; (b) the advanced presymptomatic stage manifested by a subthreshold degeneration of striatal axons and DA depletion and by a subthreshold loss of nigral cell bodies; (c) the advanced presymptomatic stage characterized by threshold depletion of striatal DA and a loss of DA-ergic axons and nigral cell bodies resulting in motor dysfunction. The degeneration of axons proceeds and prevails that of cell bodies suggesting higher sensitivity to MPTP of the former. Compensatory processes were developed in parallel to neurodegeneration that was manifested by the increase of the DA content in individual nigral cell bodies and DA turnover in the striatum. The developed models might be exploited for: (a) an examination of pathogenetic mechanisms not only in the nigrostriatal system but also in other brain regions and in the periphery; (b) a study of the compensatory mechanisms under DA deficiency; (c) a search of precursors of motor disorders and peripheral biomarkers in presymptomatic parkinsonism; (d) the development of preventive therapy aiming to slow down the neurodegeneration and strengthen compensatory processes. Thus, the models of the early and advanced presymptomaic stages and of the early symptomatic stage of parkinsonism were developed in mice with MPTP.
authors.affiliation: Laboratory of Hormonal Regulations, Institute of Developmental Biology RAS, 26 Vavilov Street, Moscow 119334, Russia. michael.ugrumov@mail.ru
authors.forename: M V
authors.initials: MV
authors.lastname: Ugrumov
authors.forename: V G
authors.initials: VG
authors.lastname: Khaindrava
authors.forename: E A
authors.initials: EA
authors.lastname: Kozina
authors.forename: V G
authors.initials: VG
authors.lastname: Kucheryanu
authors.forename: E V
authors.initials: EV
authors.lastname: Bocharov
authors.forename: G N
authors.initials: GN
authors.lastname: Kryzhanovsky
authors.forename: V S
authors.initials: VS
authors.lastname: Kudrin
authors.forename: V B
authors.initials: VB
authors.lastname: Narkevich
authors.forename: P M
authors.initials: PM
authors.lastname: Klodt
authors.forename: K S
authors.initials: KS
authors.lastname: Rayevsky
authors.forename: T S
authors.initials: TS
authors.lastname: Pronina
mesh_terms: D000818:Animals; D003342:Corpus Striatum / Q000473:pathology / Q000503:physiopathology*; D004195:Disease Models, Animal; D004298:Dopamine / Q000172:deficiency*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009410:Nerve Degeneration / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D009434:Neural Pathways / Q000473:pathology / Q000503:physiopathology*; D020734:Parkinsonian Disorders / Q000503:physiopathology*; D013378:Substantia Nigra / Q000473:pathology / Q000503:physiopathology*
chemical_list: D004298:Dopamine